Skip to main content

Minolira Side Effects

Generic name: minocycline

Medically reviewed by Drugs.com. Last updated on Apr 14, 2022.

Note: This document contains side effect information about minocycline. Some of the dosage forms listed on this page may not apply to the brand name Minolira.

For the Consumer

Applies to minocycline: oral capsule, oral capsule extended release, oral tablet, oral tablet extended release

Other dosage forms:

Side effects requiring immediate medical attention

Along with its needed effects, minocycline (the active ingredient contained in Minolira) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking minocycline:

Incidence not known

  • Black, tarry stools
  • blistering, peeling, or loosening of the skin
  • blood in the urine or stools
  • blurred or double vision
  • bulging soft spot on the head of an infant
  • chest pain, possibly moving to the left arm, neck, or shoulder
  • confusion
  • diarrhea
  • dizziness or lightheadedness
  • eye pain
  • fast heartbeat
  • general feeling of discomfort or illness
  • general tiredness and weakness
  • hives, itching, or skin rash
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • nausea or vomiting
  • red skin lesions, often with a purple center
  • severe headache
  • severe stomach pain
  • sores, ulcers, or white spots on the lips or in the mouth
  • troubled breathing
  • unusual bleeding or bruising
  • upper right abdominal or stomach pain
  • yellow eyes and skin

Side effects not requiring immediate medical attention

Some side effects of minocycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Continuing ringing or buzzing or other unexplained noise in the ears
  • difficulty with moving
  • hearing loss
  • hives or welts
  • muscle stiffness
  • redness of the skin
  • sleepiness or unusual drowsiness

Incidence not known

  • Bloating
  • discoloration of the tooth
  • increased sensitivity of the skin to sunlight
  • indigestion
  • severe sunburn

For Healthcare Professionals

Applies to minocycline: intravenous powder for injection, oral capsule, oral capsule extended release, oral suspension, oral tablet, oral tablet extended release, oral and topical kit

Nervous system

Very common (10% or more): Headache (up to 23%)

Common (1% to 10%): Dizziness (lightheadedness), somnolence, tinnitus, vertigo

Rare (0.01% to 0.1%): Hypoesthesia, paresthesia, intracranial hypertension, impaired/decreased hearing

Very rare (less than 0.01%): Bulging fontanels (in infants)

Frequency not reported: Convulsions, sedation, ataxia, benign intracranial hypertension (pseudotumor cerebri), vestibular reactions[Ref]

Headache, dizziness, vertigo. and ataxia have been reported. These side effects were reversible within 3 to 48 hours of stopping therapy and occurred less often with low doses.

Pseudotumor cerebri, bulging fontanels (infants), and decreased hearing have also been reported during postmarketing experience.[Ref]

Dermatologic

Hyperpigmentation of various body sites (including the skin, nails, teeth, oral mucosa, bones, thyroid, eyes [including sclera, conjunctiva], breast milk, lacrimal secretions, perspiration) has been reported. This blue/black/grey or muddy-brown discoloration was localized or diffuse. The most common site was the skin. Pigmentation often reversed when the drug was discontinued; however, resolution took several months or persisted in some cases. The generalized muddy-brown skin pigmentation sometimes persisted, especially in areas exposed to sun.

Biopsies of pigmented tissue have shown granules within the cells which stained positive for iron. This pigmentation faded over time after drug discontinuation.

DRESS syndrome (including fatal cases) has been reported. DRESS syndrome with persistent myocarditis has been reported in at least 3 cases.

Fixed drug eruptions, erythema multiforme, Stevens-Johnson syndrome, and photosensitivity have also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Pruritus, urticaria

Rare (0.01% to 0.1%): Alopecia, erythema multiforme, erythema nodosum, fixed drug eruptions, hyperpigmentation (brownish or bluish-black pigmentation) of skin, photosensitivity, rash, vasculitis

Very rare (less than 0.01%): Angioedema, exfoliative dermatitis, hyperpigmentation of nails/nail beds, Stevens-Johnson syndrome, toxic epidermal necrolysis

Frequency not reported: Hyperpigmentation of various body sites (including bones, mucous membranes, teeth, oral mucosa, tongue, thyroid, eyes [including sclera, conjunctiva], breast milk, lacrimal secretions, structures of inner organs), maculopapular rash, erythematous rash, discolored perspiration, Sweet's syndrome (acute febrile neutrophilic dermatosis)

Postmarketing reports: Anaphylactoid purpura, pigmentation of skin and mucous membranes, angioneurotic edema, drug rash with eosinophilia and systemic symptoms (DRESS)[Ref]

Gastrointestinal

Common (1% to 10%): Dry mouth

Rare (0.01% to 0.1%): Diarrhea, nausea, stomatitis, discoloration of teeth, vomiting

Very rare (less than 0.01%): Oral and anogenital candidiasis, dyspepsia, dysphagia, enamel hypoplasia, enterocolitis, esophagitis, esophageal ulcerations, glossitis, pancreatitis, pseudomembranous colitis

Frequency not reported: Antibiotic-associated colitis, oral cavity discoloration (including buccal mucosa, tongue, lip, gum), abdominal cramping, inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions[Ref]

Pancreatitis has rarely been associated with use of this drug. In 2 case reports, cystic fibrosis patients experienced pancreatitis during treatment with this drug for acute bacterial exacerbations of respiratory disease. The authors suggested that cystic fibrosis patients, as a result of the disease process, may be more susceptible to drug-induced pancreatitis. Additionally, in at least 1 case, multiple concomitant medications were taken; therefore, a temporal relationship between this drug and pancreatitis could not be proven conclusively.

Esophagitis and esophageal ulcerations have been reported in patients taking the capsule or tablet formulations of tetracycline-class antibiotics. Most of these patients took the drug immediately before going to bed.

Enterocolitis, pancreatitis, glossitis, dysphagia, and tooth discoloration have also been reported during postmarketing experience.[Ref]

Musculoskeletal

Lupus-like reactions induced by this drug have commonly presented with arthralgia or arthritis, myalgia or malaise, and positive ANA titer. Patients with highly positive anti-double stranded DNA (anti-dsDNA) antibodies have rarely been reported. All patients recovered after the drug was discontinued; however, several required short courses of corticosteroids.

Severe acute myopathy associated with this drug (100 mg orally per day) occurred in a 17-year-old male after strenuous exercise. His laboratory values were as follows: ESR 33 mm/hr, CRP 0.84 mg/dL, creatine kinase 87,297 units/L, AST 1307 units/L, ALT 311 units/L, LDH 4935 units/L, aldolase 12.6 units/L, alkaline phosphatase 145 units/L, GGT 66 units/L. Muscle enzyme levels normalized and his symptoms resolved 1 month after this drug was discontinued.

IV minocycline (the active ingredient contained in Minolira) plus quinupristin-dalfopristin were associated with myalgia and arthralgia in 36% of neutropenic cancer patients (n=56).[Ref]

Common (1% to 10%): Arthralgia, myalgia

Rare (0.01% to 0.1%): Lupus-like syndrome (consisting of positive antinuclear antibody [ANA], arthralgia, arthritis, joint stiffness/swelling, and at least 1 of the following: fever, myalgia, hepatitis, rash, vasculitis)

Very rare (less than 0.01%): Arthritis, bone discoloration, systemic lupus erythematosus (SLE), exacerbation of SLE, joint stiffness, joint swelling, joint discoloration, myopathy, hypersensitivity-associated rhabdomyolysis

Postmarketing reports: Polyarthralgia, exacerbation of systemic lupus, transient lupus-like syndrome[Ref]

Other

Common (1% to 10%): Fatigue, malaise

Uncommon (0.1% to 1%): Fever

Very rare (less than 0.01%): Discoloration of secretions

Injection:

-Frequency not reported: Magnesium intoxication (including flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression, respiratory paralysis)[Ref]

Psychiatric

Common (1% to 10%): Mood alteration

Hypersensitivity

Death has been reported in some cases involving hypersensitivity syndrome, serum sickness-like syndrome, and lupus-like syndrome.

Pulmonary infiltrates, night sweats, fever, and eosinophilia have developed in several patients receiving this drug. These effects were thought to be due to drug hypersensitivity.

Case reports have described a severe CNS -pulmonary hypersensitivity syndrome requiring high-dose corticosteroid therapy. Signs and symptoms have included dry cough, fever, ataxia, muscle weakness, numbness, visual abnormalities, abnormal brain MRI, seizures, pulmonary infiltrates, elevated serum IgE, elevated erythrocyte sedimentation rate (ESR), and eosinophilia.

Eosinophilic pneumonia with relapsing acute respiratory failure requiring mechanical ventilation and corticosteroids has been reported in a 54-year-old woman. Initial symptoms included dry cough, low-grade fever, fatigue, and dyspnea. Eosinophilia, elevated leukocytes, and C-reactive protein (CRP) were noted. At 14 days after being discharged and resuming this drug, the patient developed rapidly progressive respiratory failure again requiring mechanical ventilation.

Late-onset drug fever (associated with fever, sore throat, abdominal pain, weakness, loose bloody stools, fatigue, 40-pound weight loss, ESR 99 mm/hr, CRP 5 mg/dL, and mild increases in liver enzymes) has been reported in a 15-year-old boy after using this drug for 24 months for acne. After 1 year of therapy, at least 1 other case of late-onset drug fever occurred. Other reported cases of drug fever generally occurred after 2 to 4 weeks of drug exposure.[Ref]

Rare (0.01% to 0.1%): Anaphylaxis/anaphylactoid reaction (including shock, fatalities)

Frequency not reported: Hypersensitivity, hypersensitivity syndrome (consisting of cutaneous reaction [e.g., rash, exfoliative dermatitis], eosinophilia, and at least 1 of the following: hepatitis, pneumonitis, nephritis, myocarditis, pericarditis; with or without fever, lymphadenopathy), serum sickness-like syndrome (consisting of fever, urticaria/rash, arthralgia, arthritis, joint stiffness/swelling, lymphadenopathy; with or without eosinophilia), autoimmune vasculitis, drug fever, eosinophilic pneumonitis, drug hypersensitivity (e.g., pulmonary infiltrates, night sweats, fever, eosinophilia), serum sickness, serum sickness-like reactions, severe central nervous system (CNS)-pulmonary hypersensitivity syndrome

Postmarketing reports: Hypersensitivity reactions, anaphylaxis[Ref]

Immunologic

Frequency not reported: Positive antineutrophil cytoplasmic antibody (ANCA) titers, polyarteritis nodosa, ANCA-positive crescentic glomerulonephritis, ANCA-positive vasculitis, autoimmune hepatitis, necrotizing vasculitis and systemic reactions[Ref]

Rare cases of necrotizing vasculitis and systemic reactions have been reported, characterized by lymphadenopathy, eosinophilia, increased liver function enzyme levels, and dermatologic involvement. In each case, this drug was discontinued and in some cases, corticosteroid therapy was necessary to assist in the resolution of symptoms.[Ref]

Hepatic

Rare (0.01% to 0.1%): Increased liver enzymes, hepatitis, autoimmune hepatitis/hepatotoxicity

Very rare (less than 0.01%): Hepatic cholestasis, hepatic failure (including fatalities), hyperbilirubinemia, jaundice

Frequency not reported: Autoimmune hepatitis with lupus-like symptoms, increased liver function test values, acute hepatic failure, liver injury, acute hypersensitivity hepatitis associated with eosinophilia and dermatitis[Ref]

Some hepatic reactions had an autoimmune basis and occurred after several months of therapy.

In 1 case, a patient developed rapidly progressing liver failure after using this drug for 4 weeks for acne. The patient had stopped this drug 2 weeks prior to onset of malaise. Liver transplantation was considered, but the patient slowly recovered without significant intervention.

Other reports of immunologically-mediated progressive liver dysfunction have rarely occurred. In 1 case, a patient received a liver transplant after fulminant hepatic failure which was thought to be related to a 3-year history of daily therapy to treat acne. The dose of this drug ranged from 50 to 200 mg/day. A second patient had been using this drug to treat acne for 1 year just prior to seeking medical attention for an "influenza-like" syndrome. Upon hospitalization, it was determined that the patient was experiencing an autoimmune-mediated hepatitis, most probably related to this drug. Resolution of symptoms occurred in both of these cases after therapy was discontinued and each patient had received appropriate supportive medical care.

Hepatitis and liver failure have also been reported during postmarketing experience.[Ref]

Renal

Rare (0.01% to 0.1%): Increased BUN/serum urea, interstitial nephritis, acute renal failure

Postmarketing reports: Reversible acute renal failure

Tetracyclines:

-Frequency not reported: Aggravation of preexisting renal failure, azotemia/uremia, nephrotoxicity (associated with acute fatty liver), renal tubular damage, Fanconi-like syndrome[Ref]

Nephrotoxicity associated with acute fatty liver has been reported with high tetracycline doses. High serum levels of tetracyclines have been associated with azotemia, hyperphosphatemia, and acidosis in patients with renal dysfunction.

Degraded tetracycline may cause renal tubular damage and a Fanconi-like syndrome.[Ref]

Hematologic

Rare (0.01% to 0.1%): Eosinophilia, leukopenia, neutropenia, thrombocytopenia

Very rare (less than 0.01%): Hemolytic anemia, pancytopenia

Frequency not reported: Agranulocytosis, antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis[Ref]

Hemolytic anemia, thrombocytopenia, and eosinophilia have also been reported during postmarketing experience.[Ref]

Respiratory

Rare (0.01% to 0.1%): Cough, dyspnea, pulmonary infiltration

Very rare (less than 0.01%): Bronchospasm, exacerbation of asthma, pulmonary eosinophilia

Frequency not reported: Pneumonitis, hypersensitivity pneumonitis, pulmonary lupus, eosinophilic pneumonia, pleural effusions, relapsing acute respiratory failure

Postmarketing reports: Pulmonary infiltrates with eosinophilia[Ref]

Cardiovascular

Rare (0.01% to 0.1%): Myocarditis, pericarditis[Ref]

Metabolic

Rare (0.01% to 0.1%): Anorexia

Tetracyclines:

-Frequency not reported: Hyperphosphatemia, acidosis[Ref]

High serum levels of tetracyclines have been associated with azotemia, hyperphosphatemia, and acidosis in patients with renal dysfunction.[Ref]

Endocrine

A condition characterized by dark pigmentation (brown-black microscopic discoloration) of the thyroid gland has been reported; however, there was no clinical or laboratory evidence of thyroid dysfunction (unknown clinical implications).

Brown-black microscopic thyroid discoloration and abnormal thyroid function have also been reported during postmarketing experience.[Ref]

Very rare (less than 0.01%): Abnormal thyroid function, brown-black microscopic thyroid discoloration

Frequency not reported: Discolored breast secretions[Ref]

Genitourinary

Very rare (less than 0.01%): Balanitis (due to lesions on the glans penis), vulvovaginitis

Postmarketing reports: Deleterious effects on spermatogenesis[Ref]

Balanitis has also been reported during postmarketing experience.[Ref]

Local

Frequency not reported: Injection site erythema, injection site pain[Ref]

Oncologic

Frequency not reported: Papillary thyroid cancer

Postmarketing reports: Thyroid cancer

Ocular

Cases of grey scleral pigmentation and macular pigmentation have been reported in elderly patients after chronic use of this drug (5 to 12 years).[Ref]

Frequency not reported: Discoloration of conjunctiva, discoloration of lacrimal secretions, grey scleral pigmentation, macular pigmentation[Ref]

References

1. Joy VA "Minocycline and ototoxicity." N Engl J Med 301 (1979): 1450

2. Friedlander IR "Minocycline and ototoxicity." N Engl J Med 1301 (1979): 1450-1

3. Delaney RA, Narayanaswamy TR "Pseudo-tumor cerebri and acne." Mil Med 155 (1990): 511

4. Dufour H, Graziani N, Grisoli F, Donnet A "Minocycline and benign intracranial hypertension." Biomed Pharmacother 46 (1992): 171-2

5. "Product Information. Minocin (minocycline)." Lederle Laboratories (2002):

6. Kearney PJ, Lewis PA "Pseudotumor cerebri induced by minocycline treatment for acne vulgaris." Acta Derm Venereol 77 (1997): 83

7. Chiu AM, Cornblath WT, Eggenberger ER, Chuenkongkaew WL, Dotan SA, Digre KB, Musson KH, Trobe JD "Minocycline treatment and pseudotumor cerebri syndrome." Am J Ophthalmol 126 (1998): 116-21

8. Maher JD, Johnson BW, Matteson EL "Arthralgias, myalgias, and autoimmune hepatitis with minocycline therapy." J Rheumatol 25 (1998): 1653-4

9. Weese-Mayer DE, Mayer JR, Zaparackas Z, Yang RJ "Minocycline and Pseudotumor cerebri: The well-known but well-kept secret." Pediatrics 108 (2001): 519-20

10. Gertner E, Groth T, Settgast AM "Minocycline-induced central nervous system-pulmonary hypersensitivity syndrome." Int J Dermatol 42 (2003): 316-7

11. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

12. Cerner Multum, Inc. "Australian Product Information." O 0

13. Caro I "Discoloration of the teeth related to minocycline therapy for acne." J Am Acad Dermatol 3 (1980): 317-8

14. McGrae JD, Zelickson AS "Skin pigmentation secondary to minocycline therapy." Arch Dermatol 116 (1980): 1262-5

15. Wolfe ID, Reichmister J "Minocycline hyperpigmentation: skin, tooth, nail, and bone involvement." Cutis 33 (1984): 457-8

16. Iatropoulos MJ, Sparano BM, Gordon G "Hyperpigmentation of the skin associated with minocycline therapy." Arch Dermatol 121 (1985): 618-23

17. Reizner GT, Bridges AJ, Calhoun W, Graziano FM "Hyperpigmentation, neutrophilic alveolitis, and erythema nodosum resulting from minocycline." J Am Acad Dermatol 22 (1990): 959-62

18. Kowalzick L, Mensing H "Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline." Dermatologica 182 (1991): 43-6

19. Cohen PR, Meyerson MA, Hymes SR "Lingual hyperpigmentation associated with minocycline therapy." Oral Surg Oral Med Oral Pathol 79 (1995): 180-4

20. Hodgson RP, Odell EW, Haskell R "Oral presentation of minocycline-induced black bone disease." Oral Surg Oral Med Oral Pathol 79 (1995): 459-61

21. Katz J, Langevitz P, Barak S, Shemer J, Livneh A "Black tongue associated with minocycline therapy." Arch Dermatol 131 (1995): 620

22. Caldwell JB, James WD, Hung PH "Minocycline-induced hyperpigmentation." J Fam Pract 41 (1995): 183-5

23. Billick RC, Srolovitz H, Thibault MJ "Minocycline-induced Sweet's syndrome." J Am Acad Dermatol 27 (1992): 801-4

24. Barnetson RS, Fleming CJ, Hunt MJ, Mccarthy SW, Salisbury ELC "Minocycline-induced hyperpigmentation in leprosy." Br J Dermatol 134 (1996): 784-7

25. Barnhill RL, Tsao H, Busam K, Dover JS "Treatment of minocycline-induced hyperpigmentation with the q-switched ruby laser." Arch Dermatol 132 (1996): 1250-1

26. Yamamoto T, Minatohara K "Minocycline-induced acute generalized exanthematous pustulosis in a patient with generalized pustular psoriasis showing elevated level of sELAM-1." Acta Derm Venereol 77 (1997): 168-9

27. Caspi D, Brautbar C, Vardinon N, Yaron M, Burke M, Elkayam O, Levartovsky D "Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena." Am J Med 105 (1998): 484-7

28. Tanzi EL, Hecker MS "Minocycline-induced hyperpigmentation of the tongue." Arch Dermatol 136 (2000): 427-8

29. Francomano CA, McInerney A, Elkayam O, Ho NC, Levy H "Minocycline-induced generalized postinflammatory elastolysis." Am J Med 109 (2000): 340-1

30. Bolognia JL, Davidson DM, McNiff JM, Schaffer J "Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris." J Am Acad Dermatol 44 (2001): 198-206

31. Misbah S, Emery P, MarzoOrtega H "Minocycline induced autoimmune disease in rheumatoid arthritis: A missed diagnosis?." Journal of Rheumatology 28 (2001): 377-8

32. Khan Durani B, Jappe U "Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature." Br J Dermatol 147 (2002): 558-62

33. Peyriere H, Breton H, Dereure O, et al. "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?" Br J Dermatol 155 (2006): 422-8

34. Durso SC, Huq F "Spurious bruising in a patient taking warfarin: minocycline-induced skin hyperpigmentation." J Am Geriatr Soc 56 (2008): 1156-7

35. Leung WW, Tavares J "Discoloration of nail beds and skin from minocycline." CMAJ 183 (2011): 224

36. Wetter DA "Minocycline hyperpigmentation." Mayo Clin Proc 87 (2012): e33

37. Brand R, Kalai C, Yu L "Minocycline-induced Sweet syndrome (acute febrile neutrophilic dermatosis)." J Am Acad Dermatol 67 (2012): e289-91

38. Boyle MP "Minocycline-induced pancreatitis in cystic fibrosis." Chest 119 (2001): 1283-5

39. Matsuura T, Kano S, Fujimoto H, Miyazaki T, Shimizu Y "Minocycline-related lupus." Lancet 340 (1992): 1553

40. Hughes GRV, Khamashta MA, Leandro MJ, Knights SE "Minocycline-induced arthritis." Clin Exp Rheumatol 16 (1998): 587-90

41. Hanna H, Raad I, Hachem R, et al. "Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline." Antimicrob Agents Chemother 45 (2001): 3202-4

42. "Minocycline hypersensitivity syndrome manifesting with rhabdomyolysis." Int J Dermatol 41 (2002): 530-531

43. Vilaseca-Momplet J, Narvaez J "Severe acute myopathy induced by minocycline." Am J Med 116 (2004): 282-3

44. Chatham WW, Ross DW "Leukemoid blood reaction to tetracycline." South Med J 76 (1983): 1195-6

45. Otero M, Goodpasture HC "Pulmonary infiltrates and eosinophilia from minocycline." JAMA 250 (1983): 2602

46. LePaw MI "Fixed drug eruption due to minocycline-report of one case." J Am Acad Dermatol 8 (1983): 263-4

47. Rosin MA "Viral-like syndrome associated with minocycline." Arch Dermatol 120 (1984): 575

48. Shoji A, Hamada T, Someda Y "Stevens-Johnson syndrome due to minocycline therapy." Arch Dermatol 123 (1987): 18-20

49. Cuevas M, Fernandez-Rivas M, Urena V, Fraj J, Puyana J, Quirce S "Serum sickness-like syndrome associated with minocycline therapy." Allergy 45 (1990): 313-5

50. Gorard DA "Late-onset drug fever associated with minocycline." Postgrad Med J 66 (1990): 404-5

51. Autran B, Guillon JN, Joly P, et al. "Minocycline-induced cell-mediated hypersensitivity pneumonitis." Ann Intern Med 117 (1992): 476-81

52. Azarian R, Bidel N, Braud ML, Camus P, Deblay F, Dussopt C, Fourme T, Piard F, Lebargy F, Sitbon O "Minocycline pneumonitis and eosinophilia - a report on eight patients." Arch Intern Med 154 (1994): 1633-40

53. Beer JH, Kaufmann D, Pichler W "Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne." Arch Intern Med 154 (1994): 1983-4

54. Mchugh N, Quilty B "Lupus-like syndrome associated with the use of minocycline." Br J Rheumatol 33 (1994): 1197-8

55. Gordon PM, Herriot R, Reid DM, Martin JC, White MI "Minocycline-associated lupus erythematosus." Br J Dermatol 132 (1995): 120-1

56. Dykhuizen RS, Legge JS "Minocycline induced pulmonary eosinophilia." Respir Med 89 (1995): 61-2

57. Guyetrousset P, Bastujigarin S, Revuz J, Roujeau JC, Erner J, Lobut JB, Parneixspake A "Minocycline as possible cause of severe and protracted hypersensitivity drug reaction." Arch Dermatol 131 (1995): 490-1

58. Dykhuizen RS, Godden DJ, Jegarajah S, Legge JS, Zaidi AM "Lesson of the week: minocycline and pulmonary eosinophilia." BMJ 310 (1995): 1520-1

59. Cordier JF, Donne C, Loire R, Piperno D "Bronchiolitis obliterans organizing pneumonia associated with minocycline therapy: a possible cause." Eur Respir J 8 (1995): 1018-20

60. Moss C, Ferner RE "Minocycline for acne - first line antibacterial treatment of acne should be with tetracycline or oxytetracycline." BMJ 312 (1996): 138

61. Macneil M, Haase DA, Marrie TJ, Tremaine R "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline." J Am Acad Dermatol 36 (1997): 347-50

62. Bar-Kana Y, Bentur L, Livni E, et al. "Severe minocycline-induced eosinophilic pneumonia: extrapulmonary manifesations and the use of in vitro immunoassays." Ann Pharmacother 31 (1997): 733-5

63. Knowles SR, Shear NH, Shapiro LE "Comparative safety of tetracycline, minocycline, and doxycycline." Arch Dermatol 133 (1997): 1224-30

64. Akin E, Tucker LB, Miller LC "Minocycline-induced lupus in adolescents." Pediatrics 101 (1998): 926-8

65. Bajaj V, Berkelhammer C, Bhat G, Sokalski S, Jordan J, Marshall R "Minocycline-induced hepatitis with autoimmune features and neutropenia." J Clin Gastroenterol 27 (1998): 74-5

66. Hara H, Morishima T, Yamaguchi ZI, Fujitsuka A, Kurihara N, Morishima C "Severe drug-induced pneumonitis associated with minocycline and nicotinamide therapy of a bullous pemphigoid." Acta Derm Venereol 78 (1998): 393-4

67. Hess EV "Minocycline and autoimmunity." Clin Exp Rheumatol 16 (1998): 519-21

68. Jonas MM, Teitelbaum JE, Bousvaros A, Cohen M, PerezAtayde AR "Minocycline-related autoimmune hepatitis: Case series and literature review." Arch Pediatr Adolesc Med 152 (1998): 1132-6

69. Angulo JM, Espinoza LR, Sigal LH "Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis." Semin Arthritis Rheum 28 (1998): 187-92

70. Callen JP, Schrodt BJ "Polyarteritis nodosa attributable to minocycline treatment for acne vulgaris." Pediatrics 103 (1999): 503-5

71. Meier CR, Sturkenboom MCJM, Jick H, Stricker BHC "Minocycline and lupuslike syndrome in acne patients." Arch Intern Med 159 (1999): 493-7

72. Emmanuel P, Schnapf BM, Cawkwell GD, Christodoulou CS, Good RA, Ray RA "Respiratory distress due to minocycline-induced pulmonary lupus." Chest 115 (1999): 1471-3

73. Angulo JM, Espinoza LR, Sigal LH "Minocycline induced lupus and autoimmune hepatitis." J Rheumatol 26 (1999): 1420-1

74. Pohle T, Menzel J, Domschke W "Minocycline and fulminant hepatic failure necessitating liver transplantation." Am J Gastroenterol 95 (2000): 560-1

75. Biaggi A, EclacheSaudreau V, Kettaneh A, GuettierBouttier C, Lejeune F, Thomas M, Fain O, Ziol M "Minocycline-induced systemic adverse reaction with liver and bone marrow granulomas and Sezary-like cells." Am J Med 108 (2000): 353-4

76. Dhar S, Malakar RS, Malakar S "Is serum sickness an uncommon adverse effect of minocycline treatment?." Arch Dermatol 137 (2001): 100-1

77. Ofotokun I, Grim SA, Romanelli F, Jennings PR "Late-onset drug fever associated with minocycline: case report and review of the literature." Pharmacotherapy 23 (2003): 1659-62

78. Chiladakis JA, Kounis NG, Kouni SA, Kounis GN "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4

79. Bouchard SM, Salkey KS, Mohr MR, Herre JM, Shaughnessy KK "Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis." J Am Acad Dermatol 62 (2009): 315-8

80. "Drugs for rheumatoid arthritis." Treat Guidel Med Lett 7 (2009): 37-46

81. Byrne PAC, Pritchard MH, Williams BD "Minocycline-related lupus." Br J Rheumatol 33 (1994): 674-6

82. Elias E, Chapman S, Emery P, Gough A, Wagstaff K "Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome." BMJ 312 (1996): 169-72

83. Amir J, Straussberg RS, Harel L, Livni E, Varsano I "Serum-sickness-like reaction associated with minocycline therapy in adolescents." Ann Pharmacother 30 (1996): 481-3

84. Knowles SR, Shapiro L, Shear NH "Serious adverse reactions induced by minocycline: report of 13 patients and review of the literature." Arch Dermatol 132 (1996): 934-9

85. Caspi D, Yaron M, Elkayam O "Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA." Ann Rheum Dis 55 (1996): 769-71

86. Audran M, Masson C, Legrand E, Bregeon C, Chevailler A, Pascaretti C "Minocycline related lupus." J Rheumatol 23 (1996): 2160-1

87. Cremer M, Golstein PE, Deviere J "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997): 143-6

88. Stillman MT, Crosson J "Minocycline-related lupus erythematosus with associated liver disease." J Am Acad Dermatol 36 (1997): 867-8

89. Farver DK "Minocycline-induced lupus." Ann Pharmacother 31 (1997): 1160-3

90. Gordon MM, Porter D "Minocycline induced lupus: Case series in the West of Scotland." J Rheumatol 28 (2001): 1004-6

91. Balestrero S, Ciambellotti A, Parodi A, Rebora A "Minocycline-induced lupus-like syndrome." Int J Dermatol 40 (2001): 474-5

92. Sethi S, Oei LS, Sahani M "ANCA-positive crescentic glomerulonephritis associated with minocycline therapy." Am J Kidney Dis 42 (2003): E27-31

93. Bilker W, Hoffstad O, Margolis DJ "Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus." Br J Dermatol 15 (2007): 540-6

94. Affleck AG, Leach IH, Gait RC, Varma S "Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris." J Am Acad Dermatol 58(5 Suppl 1) (2008): S123-4

95. Deltenre M, Prigogine T, Burette A, De Roy G, Finet C "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984): 1491-2

96. Burke PA, Jenkins RL, Lewis D, Min DI "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992): 68-71

97. Malcolm A, Eckstein RP, Heap TR, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996): 1641-3

98. Eicher JN, Krawitt EL, Libman BS, Nietsch HH, Pansze TW, Reeves JRT "Minocycline-induced hepatitis." Am J Gastroenterol 95 (2000): 2993-5

99. MacRae KD, Farmer RDT, Seaman HE, Lawrenson RA, Williams TJ "The risk of liver damage associated with minocycline: A comparative study." J Clin Pharmacol 41 (2001): 852-60

100. Broccard AF, Liaudet L, Lepori M, Schaller MD, Oddo M "Relapsing acute respiratory failure induced by minocycline." Chest 123 (2003): 2146-8

101. Misugi K, Hasegawa H, Ohaki Y ""Black thyroid" associated with minocycline therapy." Acta Pathol Jpn 36 (1986): 1367-75

102. Moore KC, Landas SK, Bennett-Gray J, Schelper RL, Tio FO, Turner JW "Black thyroid syndrome: exaggeration of a normal process?" Am J Clin Pathol 85 (1986): 411-8

103. Bradfield YS, Link TP, Robertson DM, Rostvold JA, Salomao DR "Photo essay: minocycline-induced ocular pigmentation." Arch Ophthalmol 121 (2003): 144-5

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.